Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Marie-Pierre Campeau"'
Autor:
Houda Bahig, Marion Tonneau, Normand Blais, Philip Wong, Edith Filion, Marie-Pierre Campeau, Toni Vu, Afnan Al-Saleh, Mustapha Tehfé, Marie Florescu, David Roberge, Laura Masucci, Corentin Richard, Cynthia Menard, Bertrand Routy
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 33, Iss , Pp 115-119 (2022)
Background: Management of Non-Small Cell Lung Cancer (NSCLC) patients with oligoprogression remains controversial. There is limited data to support the strategy of Stereotactic Ablative Radiotherapy (SABR) targeting the oligoprogressive disease in co
Externí odkaz:
https://doaj.org/article/19bdc95c50cd47f29592d76bf637f3dc
Autor:
Sophie, Lavertu, Maroie, Barkati, Sylvain, Beaulieu, Jocelyne, Martin, Marie-Pierre, Campeau, David, Donath, David, Roberge
Publikováno v:
Cureus.
Purpose This study aimed to evaluate if the F18-fluorodeoxyglucose positron emission tomography (F18-FDG PET) response after two weeks of chemoradiation for locoregionally advanced esophageal cancer (staged Tumor (T) 3 and/or Nodes (N)+ Metastases (M
Autor:
Marion Tonneau, Corentin Richard, Bertrand Routy, Marie-Pierre Campeau, Toni Vu, Edith Filion, David Roberge, Dominique Mathieu, Robert Doucet, Dominic Beliveau-Nadeau, Houda Bahig
Publikováno v:
Radiotherapy and Oncology. 174:S20-S21
Autor:
Louise Lambert, Marie-Pierre Campeau, Houda Bahig, Edith Filion, Dominique Mathieu, Toni Vu, Antoine Dautruche, David Roberge
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 107:88-97
Purpose For nonoperable stage I non-small cell lung cancer, stereotactic body radiation therapy (SBRT) has emerged as a standard treatment option. We aimed to compare the clinical outcomes of lung SBRT between patients with versus without pathologic
Autor:
Vincent Cousineau Daoust, Stéphane Bedwani, Edith Filion, David Roberge, Dominique Mathieu, Laurent Bilodeau, Marie-Pierre Campeau, Houda Bahig, A. Lenglet
Publikováno v:
Practical Radiation Oncology. 9:e98-e102
Purpose We present a concise description of an in-house decision aid software called “C entral 3D” that allows a quick and robust lung tumor classification between central and peripheral as defined by the Radiation Therapy Oncology Group (RTOG) 0
Autor:
Guila Delouya, Dominic Béliveau-Nadeau, Raphael Jumeau, Marie-Pierre Campeau, David Roberge, David Donath
Publikováno v:
Digestive and Liver Disease. 50:396-400
Introduction Despite advances in treatment, notably in systemic therapy, the prognosis of pancreatic adenocarcinoma (PADC) remains dismal. Stereotactic body radiotherapy (SBRT) is an emerging tool in the complex management of PADC. We review outcomes
Autor:
Hugo Bouchard, Mikaël Simard, Andréanne Lapointe, David Roberge, Houda Bahig, Danis Blais, Edith Filion, S. Zhang, Marie-Pierre Campeau, Stéphane Bedwani, Jean-François Carrier
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:e366-e367
Autor:
Normand Blais, Elie El Rassy, Jocelyne Martin, Elie Kassouf, Samer Tabchi, Mustapha Tehfe, Hampig Raphael Kourie, Marie-Pierre Campeau
Publikováno v:
Seminars in Oncology. 44:163-177
Optimal management of patients with locally advanced non-small cell lung cancer remains challenging in the context of this heterogeneous disease. Despite aggressive therapeutic approaches, survival benefits are still unsatisfactory for what might be
Autor:
Houda Bahig, David Roberge, Dominique Mathieu, Robert Doucet, Stéphane Bedwani, Karim Zerouali, Louise Lambert, Toni Vu, Marie-Pierre Campeau, Edith Filion, Laura Masucci
Publikováno v:
Journal of Medical Imaging and Radiation Oncology. 61:543-549
INTRODUCTION The purpose of this study is quantify intrafraction motion (IFM) during lung volumetric-modulated arc therapy (VMAT) and evaluate the impact of mid-treatment cone beam computed tomography (CBCT)-guided patient repositioning on target cov
Publikováno v:
Cancer Chemotherapy and Pharmacology. 79:381-387
To date, the best chemotherapy regimen to combine with concurrent radiotherapy in stage III non-small-cell lung cancer remains undetermined. We compared the survival outcomes and toxicities in patients who were treated with etoposide–cisplatin (EP)